This prospective study included 152 elderly patients (mean age, 80 years; range, 72-88 years) with a hip fracture treated surgically. Comorbidities were evaluated, and B-type natriuretic peptide was measured at baseline and at postoperative days 4 and 5 in addition to troponin I. Major cardiac events were recorded, and 1-year mortality was assessed. Comorbidity models with the important multivariate predictors of 1-year mortality were analyzed. Overall, 9 patients (6%) experienced major cardiac events postoperatively during their hospitalization. Three patients (2%) died postoperatively, at days 5, 7, and 10, from autopsy-confirmed myocardial infarction. Three patients (2%) experienced a nonfatal myocardial infarction, and 3 patients (2%) experienced acute heart failure. At 1-year follow-up, 37 patients (24%) had died. Age older than 80 years (P=.000), renal failure (P=.016), cardiovascular disease (P=.003), respiratory disease (P=.010), Parkinson disease (P=.024), and dementia (P=.000) were univariate predictors of 1-year mortality. However, in the multivariate model, only age older than 80 years (P=.000) and dementia (P=.024) were important predictors of 1-year mortality. In all comorbidity models, age older than 80 years and dementia were important predictors of 1-year mortality. Postoperative increase in B-type natriuretic peptide was the most important predictor of 1-year mortality. Receiver operating characteristic curve analysis showed a threshold of 90 ng/mL of preoperative B-type natriuretic peptide (area under the curve=0.773, 95% confidence interval, 0.691-0.855, P<.001) had 82% sensitivity and 62% specificity to predict 1-year mortality. Similarly, a threshold of 190 ng/mL of postoperative B-type natriuretic peptide (area under the curve=0.753, 95% confidence interval, 0.662-0.844, P<.001) had 70% sensitivity and 77% specificity to predict the study endpoint. [Orthopedics. 2017; 40(3):e417-e424.] 
H ip fractures are the most common cause of morbidity and hospitalization in elderly patients, leading to 14% to 36% mortality at 1 year. 1, 2 In current clinical practice, patients undergoing hip fracture surgery tend to be older and have more concurrent medical comorbidities. 1, 3 Comorbidities such as renal failure, respiratory disease, dementia, and cancer are known to be strongly associated with long-term mortality in these patients. 1, 2, [4] [5] [6] [7] A number of cardiac biomarkers that have been intergraded in the diagnosis and therapeutics of heart failure and acute coronary syndrome patients currently are tested to improve the management of patients undergoing noncardiac surgery. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] 
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In patients undergoing noncardiac surgery, preoperative NP levels theoretically can integrate all of the parameters of cardiovascular risk. Previous studies in patients undergoing variable noncardiac procedures have confirmed the predictive value of preoperative measurement of B-type natriuretic peptide (BNP) and N-terminal prohormone of BNP (NT-proBNP). [9] [10] [11] [12] Measurement of NP in the postoperative phase may have an additive prognostic role; however, the exact clinical interpretation is unclear. 13 Troponin is considered the gold standard for the diagnosis of myocardial infarction (MI) and has revolutionized the management of patients with acute coronary syndrome.
14 Highly sensitive troponin assays may detect even subclinical myocardial injury in the postoperative period; in this setting, recent studies have associated minor increases of troponin values to the short-and long-term outcome of patients undergoing vascular and orthopedic surgery. [15] [16] [17] [18] Combined measurement of preoperative and postoperative BNP levels with postoperative troponin elevation in patients undergoing noncardiac surgery may be useful to predict the outcome of the patients undergoing noncardiac surgery. However, there are no such studies to evaluate the predictive value of combined BNP and troponin measurement in these patients.
In clinical practice, routine perioperative measurement of biomarkers can be justified if it shows incremental prognostic value compared with clinical risk stratification that may alter clinical decision making. 19 In the specific population of elderly patients undergoing hip fracture surgery, cardiac biomarkers have to prove additive clinical value to baseline comorbidities that primarily determine longterm outcome. Therefore, the authors performed this prospective study to evaluate the clinical value of routine measurement of preoperative and postoperative BNP and postoperative troponin increase in patients older than 65 years undergoing hip fracture surgery.
Materials and Methods
This prospective study included patients older than 65 years with hip fractures who were admitted and treated surgically from August 2009 to May 2011 at the authors' institutions. Patients with any contraindication for surgery according to current guidelines such as acute coronary syndrome and acute heart failure syndrome, 20 patients with multiple fractures, and patients who underwent revision operation for complications of recent hip fracture surgery were excluded.
A total of 152 patients were included in the study ( Table 1) . There were 111 women and 41 men; mean patient age was 80 years (range, 72-88 years). The endpoint of the study was all-cause mortality at 1 year after surgery; no patient was lost to the 1-year follow-up. No patient was specifically recalled for the purpose of this study; all data were assessed with direct telephone contact either with patients or their relatives. All participants or their relatives gave written informed consent for their data to be included in this study. The study was approved by the institutional review board or ethics committee of the authors' institutions.
At admission, all patients underwent a bedside preoperative physical examination. Current medications were documented, and patients' medical files, including previous hospital discharge reports, were reviewed. A surface electrocardiogram (ECG) was performed in all cases. Blood was drawn from a peripheral vein within 24 hours before operation for routine laboratory tests, including measurement of serum BNP. Measurement of BNP was performed with a chemiluminescent immunoassay-automated (CIA) analyzer (Architect 16200; Abbott Laboratories, Abbott Park, Illinois). Blood samples for BNP were centrifuged, stored at 2°C to 8°C, and tested within 24 hours.
The most common comorbidities were cardiovascular disease (22%), dementia (22%), diabetes mellitus (17%), and Parkinson disease (15%). Definition of comorbidities was based in medical history, bedside preoperative physical examination, and laboratory findings. Patients' relatives were interviewed, especially in patients with concomitant cognitive dysfunction. Renal failure was defined as a 
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laboratory preoperative creatinine value greater than 1.2 mg/mL. Cardiovascular disease was considered to be present in patients with a previous history of angina, MI, or documented heart failure. Diagnoses of respiratory disease, Parkinson disease, rheumatoid disease, psychosis, preexisting dementia, and cancer were based on clinical examination, past medical history, and current medications taken by the patients. When a patient's medical history was equivocal or illdefined, the diagnosis of comorbidities was made after consensus among the treating physicians. Age older than 80 years (dichotomized according to the mean age of the patients included in the study) also was considered a comorbidity because age has been related to the outcome of elderly patients undergoing hip fracture surgery. Eighty-two patients (54%) experienced a pertrochanteric hip fracture and were treated with intramedullary hip nailing, and 70 patients (46%) experienced a femoral neck fracture and were treated with a cemented (32 patients) or a cementless (38 patients) hip hemiarthroplasty. General anesthesia was administered in 30 patients (20%), and spinal anesthesia was administered in 122 patients (80%) based on the discretion of the treating anesthesiologists. According to the study protocol, physical examination, ECG, and blood sampling were repeated in all patients at days 4 and 5 postoperatively. In addition, repeat measurements of BNP and troponin I were obtained at the same time in all patients. Blood studies also were performed on the basis of the patients' clinical symptoms.
Major cardiac events (MACE), such as cardiac death, MI, acute heart failure, and stroke, were documented and recorded during patients' hospital stays. Patients were diagnosed with postoperative MI when there was a combination of clinical symptoms, an increase greater than 0.5 ng/mL in troponin I values, and new ECG changes such as pathologic Q waves, ST elevation, ST depression, and T wave inversion.
14 Acute heart failure syndrome was diagnosed with indicative symptoms of dyspnea, in combination with clinical signs and chest radiographic findings. Stroke and pulmonary embolism were diagnosed with computed tomography when clinically suspected. Troponin I values were considered increased if the postoperative troponin level was greater than 0.01 ng/mL.
14 Postoperative BNP increase was considered significant if there was a 100% increase compared with the preoperative value. 21 Physicians engaged in the perioperative management of patients were blinded to BNP and troponin values but not to baseline comorbidities. Although the study physicians did not perform all of the postoperative bedside evaluations, they regularly reviewed the medical files and collaborated closely with all of the treating physicians.
Statistical analyses were performed with SPSS software version 17 (SPSS Inc, Chicago, Illinois). Based on visual inspection of the histograms and KolmogorovSmirnov test, the Gaussian distribution of continuous variables was evaluated. Continuous variables were presented as mean and standard deviation if normally distributed; otherwise, they were presented as median and interquartile range.
Categorical variables were expressed as number and frequencies. Continuous variables were compared with an unpaired Student's t test or the Mann-Whitney test, and categorical variables were compared using the chi-square test or Fisher exact test as appropriate. Univariate binary logistic regression analysis was performed to explore the relation of baseline comorbidities with 1-year mortality.
Binary logistics also were used to evaluate the prognostic value of biomarkers; for this analysis, a cox regression model was not used because the aim was to test the clinically relevant binary (dead or alive) endpoint after 1 year of follow-up (for patients surviving less than 1 year, a possible conservative nonsurgical approach could be considered). For multivariate modeling, only covariates with a univariate P<.05 were used to avoid model over-fit. A comorbidity model then was derived using only independent predictors of 1-year mortality.
Multivariate analysis then was performed with 5 non-nested logistic regression models to investigate the independent correlation of the comorbidity model and cardiac biomarkers with 1-year mortality. Preoperative BNP and postoperative BNP and troponin I values were tested individually with the comorbidity model and also with an additional model combining all biomarkers. Preoperative and postoperative BNP were included in the same model because they give different clinical information (preoperative BNP is related to baseline risk, whereas postoperative BNP may be related to postoperative complications). 11, 13 Statistical tests were 2-sided, and P<.05 was considered statistically significant.
results

MACE and Cardiac Biomarkers
Overall, 9 patients (6%) experienced a MACE postoperatively during their hospitalization. Three patients (2%) died 5, 7, and 10 days postoperatively. Three patients (2%) experienced a nonfatal MI, and 3 patients (2%) experienced acute heart failure. Autopsies were performed on the 3 patients with in-hospital deaths and confirmed a cardiac-related (MI) cause of death. At the 1-year follow-up via telephone, 37 patients (24%) were reported dead; the cause of death for these patients was investigated, mainly by obtaining clinical information from the relatives. Autopsies were conducted in 5 of these patients, and the cause of death was confirmed to be related to cardiovascular and pulmonary dysfunction. Overall, 8 patients (5%) may have died of noncardiac causes (lung and urinary tract infections), although cardiovascular risk factors may have contributed to this outcome.
Overall, 43 patients (28.3%) had a significant (100%) postoperative increase in BNP, and 77 patients (51%) had a postoperative increase of more than 0.01 ng/mL in troponin I. The significant postoperative increase in BNP was not different between patients who had a postoperative MACE and those who did not have a postoperative MACE (P=.730); the increase also was not significantly different between patients who were dead or alive after 1 year of follow-up (P=.538). In contrast, the troponin I increase was significantly higher in patients who had a postoperative MACE compared with those who did not have a postoperative MACE (P=.002), as well as for patients who had died compared with the patients who were alive at the 1-year follow-up (P<.001) ( Table 2) . 
Comorbidity Models for Prediction of 1-Year Mortality
Age older than 80 years (P=.000), renal failure (P=.016), cardiovascular disease (P=.003), respiratory disease (P=.010), Parkinson disease (P=.024), and dementia (P=.000) were univariate predictors of 1-year mortality. However, in the multivariate analysis, only age older than 80 years (P=.000) and dementia (P=.024) were important predictors of 1-year mortality (Table 3) . Therefore, these 2 multivariate predictors of 1-year mortality were used further in the comorbidity models to evaluate the additive prognostic value of cardiac biomarkers ( Table 4) .
In all of the comorbidity models, age older than 80 years and dementia were important predictors of 1-year mortality. Predictors of 1-year mortality were BNP (preoperative and postoperative values) and troponin I increase. Interestingly, in the respective comorbidity model, the significant postoperative increase in BNP did not show additional prognostic value. In the comorbidity model that evaluated BNP at baseline and postoperative in- crease in addition to troponin I increase, BNP postoperative increase was the most important cardiac biomarker ( Table 4) . Receiver operating characteristic (ROC) curve analysis showed that a preoperative threshold of 90 ng/mL of BNP (area under the curve [AUC]=0.773, 95% CI, 0.691-0.855, P<.001) had an 82% sensitivity and a 62% specificity to predict 1-year mortality. Similarly, a postoperative threshold of 190 ng/mL of BNP (AUC=0.753, 95% CI, 0.662-0.844, P<.001) had a 70% sensitivity and a 77% specificity to predict the study endpoint (Figure) .
In the univariate regression analysis, there was a significant association of preoperative BNP values (hazard ratio, 1.003; 95% CI, 1.001-1.005; P=.001) and postoperative BNP values with 1-year mortality (hazard ratio, 1.003; 95% CI, 1.002-1.005; P=.000). When troponin I increase was used as a continuous variable (hazard ratio, 1.003; 95% CI, 1.002-1.005; P=.000) or a binary (>0.01 ng/mL or ≤0.01 ng/mL) value in the univariate analysis, there was also a significant relation of postoperative troponin I increase with 1-year mortality (hazard ratio, 6.517; 95% CI, 1.779-23.871; P=.005).
discussion
The current study evaluated the predictive value of preoperative and postoperative BNP values and postoperative troponin I values increase for 1-year mortality in patients undergoing hip fracture surgery. Each of the examined cardiac biomarkers was associated with 1-year mortality independently of comorbidities. However, when all biomarkers were examined in the same comorbidity model, only age older than 80 years, dementia, and BNP significant postoperative increase were independently related to 1-year mortality. Therefore, measurement of postoperative BNP may be of more decisive clinical value for these patients.
Detailed information regarding delay for surgery, blood transfusion requirements, anesthesia considerations, types of fractures, and postoperative care were not systematically collected and were not included in the analysis. Although this information probably would have been useful, including more variables would have significantly complicated this study, which primarily aimed to sensitize orthopedic surgeons on the value and possible prognostic significance of the BNP biomarker. In addition, only hip fracture patients were included in this study; therefore, other similar studies are necessary to evaluate the role of cardiac biomarkers in various noncardiac, nonorthopedic operations in elderly patients.
Hip fractures are a common factor of morbidity and death in elderly patients. In this clinical scenario, health care providers are tasked to find cost-effective strategies to improve the survival and quality of life of these patients. 22 The mortality of hip fracture patients was reduced significantly in the 1960s and early 1980s following 
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Copyright © SLACK inCorporAted n Feature Article advances in perioperative care; however, there has been no further benefit in recent decades. 3 Previous studies have reported a 14% to 36% all-cause 1-year mortality of hip fracture patients.
1,2,4-7,11,17 Associated medical comorbidities such as heart failure, 2 renal failure, 4 respiratory disease, 2,5 Parkinson disease, 6 and cancer 5 consistently have been related to the morbidity and mortality of these patients. Both increased age and a preoperative diagnosis of dementia are important risk factors of mortality in these patients. 4, 7, 11, 17 These findings also were confirmed in the present study; the overall 1-year mortality of the patients in this series was 24%, with age and dementia being important predictors of 1-year mortality.
The prognostic value of cardiac biomarkers in orthopedic patients has been reported previously. 11, 17 However, patients with dementia usually were excluded, probably because perioperative cardiac symptoms may be difficult to evaluate in these patients. 11, 17 Nevertheless, as the present study showed, this is a high-risk group of patients with significant 1-year mortality after hip fracture surgery.
Cardiac biomarkers are a new promising tool for the risk stratification of patients undergoing noncardiac surgery, yet routine measurement has not been implemented in clinical practice. Secretion of NP is triggered by multiple pathophysiologic stimuli such as myocardial stretch, ischemia, and sepsis, which are known to contribute to the surgical risk of these patients. Therefore, NP serum levels may be useful for predicting in-hospital cardiac complications and patient mortality. 8, 9, 12, 13 A few studies also have shown that BNP and NT-proBNP are predictive of short-and long-term cardiac events in elective and emergency orthopedic surgery; however, inclusion criteria of the patients in this study varied significantly, [10] [11] [12] and troponin values were not evaluated. 13 A recent study showed an independent correlation of NP preoperative elevation and dementia with outcome; however, there was no systematic analysis of all baseline significant noncardiac comorbidities, and the role of postoperative NP and troponin increase was not addressed. 23 In patients undergoing emergency orthopedic surgery, a single previous study evaluated postoperative BNP measurement; in that study, postoperative BNP was related to death or nonfatal MI at 1-year of follow-up independently of baseline BNP values. 11 However, in that study, patients with dementia were excluded.
11
The present study confirmed previous reports and showed that BNP values are important predictors of 1-year mortality in patients undergoing hip fracture surgery, independently of concomitant comorbidities. In contrast to previous reports, age and dementia are important predictors of mortality and should be considered in the evaluation of mortality for these patients.
Troponin assays are highly sensitive and tissue-specific biomarkers of myocardial necrosis. 15 Although postoperative detection of minor troponin increase without clinical symptoms or ECG findings is not considered diagnostic for MI, recent studies have related troponin increase with the short-and long-term mortality of patients undergoing noncardiac surgery. [15] [16] [17] [18] A meta-analysis showed that postoperative troponin increase was an important predictor of intermediate (<180 days) mortality of patients undergoing vascular surgery. 15 Another study of 2232 patients undergoing a variety of noncardiac procedures showed that minor postoperative troponin increase was an important predictor of all-cause 30-day mortality. 18 However, in these studies, although all of the patients were older than 60 years, important comorbidities such as dementia, Parkinson disease, and cancer were not included in the analyses. 11, 16, 17 In contrast to these reports, the present study confirmed that age older than 80 years and dementia are important predictors of 1-year mortality; in these patients, postoperative troponin increase is an important predictor of mortality, independently of comorbidities.
The present study showed that BNP postoperative increase is an important predictor of 1-year mortality after hip fracture surgery; in the respective comorbidity model, BNP postoperative increase was an important predictor of mortality, in contrast to preoperative BNP values and postoperative troponin increase. Therefore, the prognostic role of BNP postoperative increase should be acknowledged and probably should be considered more clinically relevant than troponin elevation for prediction of long-term survival following noncardiac surgery.
The predictive value of BNP significant (100%) postoperative increase also was analyzed; interestingly, a correlation with the study endpoint was not observed. A possible explanation is that patients with high baseline BNP values are already at high risk, whereas a significant BNP postoperative increase may be clinically relevant only for patients with low baseline BNP values. In addition, in contrast to previous studies, [8] [9] [10] [11] [12] [13] 16, 17 the present study included only the hard endpoint of 1-year all-cause mortality, combined all clinically relevant cardiac biomarkers, and included all patients with hip fractures with their major concomitant co- morbidities. Therefore, the current study applies to the real clinical scenario, and its results should be considered important.
Cardiovascular medical history is illdefined in many elderly patients who are admitted with a hip fracture, and postoperative symptoms of chest pain and dyspnea may be underestimated owing to opioid treatment or concomitant postoperative delirium. 24, 25 Cardiac biomarkers such as preoperative and postoperative BNP and postoperative troponin I may influence the decision for surgical treatment and predict 1-year mortality independently of age and dementia in elderly patients undergoing hip fracture surgery. Baseline BNP values may identify patients at high surgical risk and influence the decision for nonoperative treatment in borderline patients. 24 Troponin I postoperative increase may define a group of patients in need for comprehensive postoperative electrocardiogram monitoring, intensive medication treatment, and risk factor modification at discharge.
However, measurement of postoperative BNP may be of a more decisive clinical value for these patients. More importantly, postoperative BNP also may identify a high-risk subgroup of patients in need of thorough in-hospital clinical monitoring and optimization of pharmaceutical treatment when necessary. Postdischarge optimization of angiotensin-converting-enzyme inhibitors, beta-blockers, and spironolactone in this subgroup potentially may improve longterm mortality; however, this remains to be verified in large studies. Treatment of cardiovascular risk based in perioperative biomarker monitoring may be a realistic strategy to improve long-term survival of hip fracture patients, as treatment of associated comorbidities may be a difficult and complex task for physicians.
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